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In the study presented here, a new series of 2-furyl(4-{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl)
methanone derivatives was targeted. The synthesis was initiated by the treatment of different secondary 
amines (1a-h) with 4-bromomethylbenzenesulfonyl chloride (2) to obtain various 1-{[4-(bromomethyl)
phenyl]sulfonyl}amines (3a-h). 2-Furyl(1-piperazinyl)methanone (2-furoyl-1-piperazine; 4) was then 
dissolved in acetonitrile, with the addition of K2CO3, and the mixture was refluxed for activation. This 
activated molecule was further treated with equi-molar amounts of 3a-h to form targeted 2-furyl(4-
{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl)methanone derivatives (5a-h) in the same reaction 
set up. The structure confirmation of all the synthesized compounds was carried out by EI-MS, IR 
and 1H-NMR spectral analysis. The compounds showed good enzyme inhibitory activity. Compound 
5h showed excellent inhibitory effect against acetyl- and butyrylcholinesterase with respective IC50 
values of 2.91±0.001 and 4.35±0.004 μM, compared to eserine, a reference standard with IC50 values of 
0.04±0.0001 and 0.85±0.001 μM, respectively, against these enzymes. All synthesized molecules were 
active against almost all Gram-positive and Gram-negative bacterial strains tested. The cytotoxicity of 
the molecules was also checked to determine their utility as possible therapeutic agents.
Uniterms: Piperazine derivatives/antimicrobial activity. Piperazine derivatives/in silico. Piperazine 
derivatives/Cholinesterase assays. Piperazine derivatives/ hemolytic activity.
INTRODUCTION
Sulfonamides have received a lot of attention in the 
literature because of their exciting biological properties 
and their role as pharmacophores of considerable historical 
importance (Abbasi et al., 2016a, b). Heterocyclic 
sulfonamides have been found to be carbonic anhydrase 
inhibitors (Surpuran et al., 1998; Di Fiore et al., 2010; 
Smaine et al., 2008) and antibacterial (Gadad et al., 2000) 
and anticancer, antiinflammatory and analgesic (Sondhi 
et al., 2000) agents. Furthermore, the piperazine core has 
displayed a wide spectrum of pharmacological activities 
and is part of a number of drugs that are preclinical and 
clinical candidates (Welsch, Snyder, Stockwell, 2010; 
Hussain et al., 2016).
Cholinesterases (acetylcholinesterase, AChE (EC 
3.1.1.7)), butyrylcholinesterase, BChE (EC 3.1.1.8)), 
belong to the class of serine hydrolases and are responsible 
for the inactivation of acetylcholine at cholinergic 
synapses. The main effect of AChE and BChE is to catalyze 
the hydrolysis of the neurotransmitter acetylcholine and 
termination of the nerve impulse at cholinergic synapses 
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(Cygler et al., 1993). BChE is extensively present in 
Alzheimer’s plaques (Gauthier, 2001). Cholinesterases 
play an important role in Alzheimer’s disease, and so 
their inhibitors are of great importance for the treatment 
of such diseases.
The bioactivity of piperazine and sulfamoyl moieties 
prompted us to synthesize some new molecules bearing 
these moieties together. The compounds synthesized 
were screened to explore their enzyme inhibitory and 
antibacterial potential. Moreover, we also carried out 
cytotoxicity and molecular docking studies to determine 
their utility as possible therapeutic agents in drug 
development programs.
MATERIAL AND METHODS
General
Chemicals were purchased from Sigma Aldrich and 
Alfa Aesar (Germany), and solvents of analytical grade 
were from local suppliers. Melting points were taken 
uncorrected on a Griffin and George apparatus using the 
open capillary tube method. Thin layer chromatography 
(TLC) using ethylacetate:n-hexane (30:70) as mobile 
phase, with detection at 254 nm, was used to determine the 
initial purity of the compounds. IR spectra were recorded 
on a Jasco-320-A spectrometer by using the KBr pellet 
method. 1H-NMR spectra were recorded at 500 MHz in 
CDCl3 using a Bruker spectrometer. EIMS spectra were 
recorded with a JMS-HX-110 spectrometer.
Synthesis of 1-{[4-(bromomethyl)phenyl]sulfonyl}
amines (3a-h)
Different secondary amines (1a-h; 15.0 mmol) 
were suspended in 15 mL of distilled water in an iodine 
flask. The pH was adjusted to 9-10 with 10% Na2CO3, and 
4-bromomethylbenzenesulfonyl chloride (2; 15.0 mmol) 
was added dropwise to the reaction mixture in 2-5 min. 
After complete addition, the iodine flask was vigorously 
shaken (manually) until the formation of solid precipitates. 
The progress of the reaction was monitored by TLC. 
The solid obtained was filtered, washed with distilled 
water and dried to yield the corresponding electrophiles 
1-{[4-(bromomethyl)phenyl]sulfonyl}amines 3a-h.
Synthesis of 2-furyl(4-{4-[(substituted)sulfonyl]
benzyl}-1-piperazinyl)methanone derivatives (5a-h)
2-Furyl(1-piperazinyl)methanone (2-furoyl-
1-piperazine; 4; 0.1 g, 0.0045 mol) was dissolved in 
acetonitrile (20-30 mL) in a 100-mL round-bottom 
flask. Solid K2CO3 (0.0135 mol) was added and the 
mixture was refluxed for 0.5 h to activate compound 4. 
The desired electrophiles 1-{[4-(bromomethyl)phenyl]
sulfonyl}amines 3a-h, 0.0045 mol, were added separately 
in each reaction. The mixture was refluxed for 4-5 h 
for completion. TLC was carried out to check reaction 
completion. Distilled water was added to the reaction 
mixture to obtain the precipitates, which were filtered, 
washed and dried to yield the desired products 2-furyl(4-
{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl)
methanone derivatives 5a-h.
2-Furyl{4-[4-(4-morpholinylsulfonyl)benzyl]-1-
piperazinyl}methanone (5a)
Off-white amorphous solid; Yield: 90%; m.p.: 139-
141 oC; HRMS: [M]•+ 419.1517 (Calcd. for C20H25N3O5S; 
419.1604); IR (KBr, cm-1) υmax: 3081 (C-H str. of aromatic 
ring), 2878 (C-H str. of aliphatic), 1650 (C=O str.), 1578 
(C=C aromatic str.), 1428 (S=O), 1192 (C-O-C bond str.), 
1118 (C-N-C bond str.); 1H-NMR (500 MHz, CDCl3, δ/ 
ppm): 7.71 (d, J = 8.2 Hz, 2H, H-3’’ & H-5’’), 7.54 (d, J 
= 8.1 Hz, 2H, H-2’’ & H-6’’), 7.46 (distorted d, J = 1.5 
Hz, 1H, H-5’), 6.99 (d, J = 3.4 Hz, 1H, H-3’), 6.47 (dd, J 
= 1.7, 3.4 Hz, 1H, H-4’), 3.82 (br.s, 4H, CH2-2 & CH2-6), 
3.76-3.74 (m, 4H, CH2-3’’’ & CH2-5’’’), 3.61 (s, 2H, CH2-
7’’), 3.01 (m, 4H, CH2-3 & CH2-5), 2.51(m, 4H, CH2-2’’’ & 
CH2-6’’’); EIMS (m/z): 419 [M]+, 324 [C15H22N3O3S]+, 323 
[C15H21N3O3S]•+, 268 [C16H16N2O2]•+, 241 [C11H15NO3S]•+, 
240 [C11H14NO3S]+, 193 [C10H13N2O2]+,179 [C9H11N2O2]+, 
175 [C6H9NO3S]•+, 95 [C5H3O2]+, 86 [C4H8NO]+.
(4-{4-[(3,5-dimethyl-4-morpholinyl)sulfonyl]benzyl}-1-
piperazinyl)(2-Furyl)methanone (5b)
White amorphous solid; Yield: 87%; m.p.: 151-153 
oC; HRMS: [M]•+ 447.1823 (Calcd. for C22H29N3O5S; 
447.1876); IR (KBr, cm-1) υmax: 3089 (C-H str. of aromatic 
ring), 2878 (C-H str. of aliphatic), 1652 (C=O str.), 1587 
(C=C aromatic str.), 1435 (S=O), 1193 (C-O-C bond str.), 
1119 (C-N-C bond str.); 1H-NMR (500 MHz, CDCl3, δ/ 
ppm): 7.75 (d, J = 8.1 Hz, 2H, H-3’’ & H-5’’), 7.56 (d, J = 
8.1 Hz, 2H, H-2’’ & H-6’’), 7.49 (distorted d, J = 1.6 Hz, 
1H, H-5’), 7.05 (d, J = 3.4 Hz, 1H, H-3’), 6.48 (dd, J = 1.6, 
3.4 Hz, 1H, H-4’), 3.85 (br.s, 4H, CH2-2 & CH2-6), 3.82 
(m, 4H, CH2-2’’’ & CH2-6’’’), 3.76-3.74 (m, 2H, CH-3’’’ 
& CH-5’’’), 3.60 (s, 2H, CH2-7’’), 3.09 (m, 4H, CH2-3 & 
CH2-5), 1.35 (s, 6H, CH3-7’’’ & CH3-8’’’); EIMS (m/z): 
447 [M]+, 352 [C17H26N3O3S]+, 351 [C17H25N3O3S]•+, 268 
[C16H16N2O2]•+, 269 [C13H19NO3S]•+, 268 [C13H19NO3S]+, 
193 [C10H13N2O2]+,179 [C9H11N2O2]+, 203 [C8H13NO3S]•+, 
95 [C5H3O2]+, 114 [C6H12NO]+.
Synthesis and in silico study of 2-furyl(4-{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl)methanone derivatives as suitable therapeutic entrants
Braz. J. Pharm. Sci. 2017;53(1):e15237 Page 3 / 11
2-Furyl{4-[4-(1-piperidinylsulfonyl)benzyl]-1-
piperazinyl}methanone (5c)
Light brown crystalline solid; Yield: 91 %; m.p.: 60-
62 oC; HRMS: [M]•+ 417.1726 (Calcd. for C21H27N3O4S; 
417.1748); IR (KBr, cm-1) υmax: 3086 (C-H str. of aromatic 
ring), 2878 (C-H str. of aliphatic), 1659 (C=O str.), 1576 
(C=C aromatic str.), 1426 (S=O), 1191 (C-O-C bond str.), 
1109 (C-N-C bond str.); 1H-NMR (500 MHz, CDCl3, δ/ 
ppm): 7.68 (d, J = 8.2 Hz, 2H, H-3’’ & H-5’’), 7.47 (d, J = 
8.1 Hz, 2H, H-2’’ & H-6’’), 7.50-7.47 (merged s, 1H, H-5’), 
6.97 (d, J = 3.3 Hz, 1H, H-3’), 6.47 (dd, J = 1.7, 3.3 Hz, 1H, 
H-4’), 3.76 (br.s, 4H, CH2-2 & CH2-6), 3.52 (s, 2H, CH2-
7’’), 2.98 (m, 4H, CH2-3 & CH2-5), 2.92 (m, 4H, CH2-2’’’ & 
CH2-6’’’), 1.59(m, 4H, CH2-3’’’ & CH2-5’’’), 1.50 (m, 2H, 
CH2-4’’’); EIMS (m/z): 417 [M]+, 322 [C16H24N3O2S]+, 321 
[C16H23N3O2S]•+, 268 [C16H16N2O2]•+, 239 [C12H17NO2S]•+, 
238 [C12H16NO2S]+, 193 [C10H13N2O2]+,179 [C9H11N2O2]+, 
173 [C7H11NO2S]•+, 95 [C5H3O2]+, 84 [C5H10N]+.
2-Furyl(4-{4-[(2-methyl-1-piperidinyl)sulfonyl]benzyl}-1-
piperazinyl)methanone (5d)
Brown amorphous solid; Yield: 85 %; m.p.: 81-83 
oC; HRMS: [M]•+ 431.1873 (Calcd. for C22H29N3O4S; 
431.1889); IR (KBr, cm-1) υmax: 3092 (C-H str. of aromatic 
ring), 2880 (C-H str. of aliphatic), 1663 (C=O str.), 1584 
(C=C aromatic str.), 1433 (S=O), 1195 (C-O-C bond str.), 
1121 (C-N-C bond str.); 1H-NMR (500 MHz, CDCl3, 
δ/ ppm): 7.60 (d, J = 8.2 Hz, 2H, H-3’’ & H-5’’), 7.45 (d, J 
= 8.2 Hz, 2H, H-2’’ & H-6’’), 7.48 (distorted d, J = 1.5 Hz, 
1H, H-5’), 6.98 (d, J = 3.4 Hz, 1H, H-3’), 6.49 (dd, J = 1.5, 
3.3 Hz, 1H, H-4’), 3.79 (br.s, 4H, CH2-2 & CH2-6), 3.59 
(s, 2H, CH2-7’’), 2.99 (m, 4H, CH2-3 & CH2-5), 2.92 (m, 
1H, CH2-2’’’), 2.75 (m, 2H, CH2-6’’’), 1.95-1.46 (m, 6H, 
CH2-3’’’ - CH2-5’’’), 0.96 (s, 3H, CH3-7’’’); EIMS (m/z): 
431[M]+, 336 [C17H26N3O2S]+, 335 [C17H25N3O2S]•+, 268 
[C16H16N2O2]•+, 253 [C13H19NO2S]•+, 252 [C13H18NO2S]+, 
193 [C10H13N2O2]+,179 [C9H11N2O2]+, 187 [C8H13NO2S]•+, 
95 [C5H3O2]+, 98 [C6H12N]+.
2-Furyl(4-{4-[(3-methyl-1-piperidinyl)sulfonyl]
benzyl}-1-piperazinyl)methanone (5e)
Brown amorphous solid; Yield: 80%; m.p.: 80-82 
oC; HRMS: [M]•+ 431.1873 (Calcd. for C22H29N3O4S; 
431.1889); IR (KBr, cm-1) υmax: 3089 (C-H str. of aromatic 
ring), 2876 (C-H str. of aliphatic), 1654 (C=O str.), 1579 
(C=C aromatic str.), 1431 (S=O), 1189 (C-O-C bond str.), 
1115 (C-N-C bond str.); 1H-NMR (500 MHz, CDCl3, δ/ 
ppm): 7.69 (d, J = 8.1 Hz, 2H, H-3’’ & H-5’’), 7.45 (d, J 
= 8.1 Hz, 2H, H-2’’ & H-6’’), 7.51 (distorted d, J = 1.4 
Hz, 1H, H-5’), 7.03 (d, J = 3.3 Hz, 1H, H-3’), 6.43 (dd, 
J = 1.5, 3.3 Hz, 1H, H-4’), 3.84 (br.s, 4H, CH2-2 & CH2-
6), 3.46 (s, 2H, CH2-7’’), 3.07 (m, 4H, CH2-3 & CH2-5), 
2.90-2.60 (m, 4H, CH2-2’’’ & CH2-6’’’), 1.75 (m, 1H, CH2-
3’’’), 1.81-1.48 (m, 4H, CH2-4’’’ & CH2-5’’’), 0.98 (s, 3H, 
CH3-7’’’); EIMS (m/z): 431[M]+, 336 [C17H26N3O2S]+, 335 
[C17H25N3O2S]•+, 268 [C16H16N2O2]•+, 253 [C13H19NO2S]•+, 
252 [C13H18NO2S]+, 193 [C10H13N2O2]+,179 [C9H11N2O2]+, 
187 [C8H13NO2S]•+, 95 [C5H3O2]+, 98 [C6H12N]+.
2-Furyl(4-{4-[(4-methyl-1-piperidinyl)sulfonyl]benzyl}-1-
piperazinyl)methanone (5f)
Light brown amorphous solid; Yield: 87%; m.p.: 86-
88 oC; HRMS: [M]•+ 431.1873 (Calcd. for C22H29N3O4S; 
431.1889); IR (KBr, cm-1) υmax: 3086 (C-H str. of aromatic 
ring), 2877 (C-H str. of aliphatic), 1657 (C=O str.), 1580 
(C=C aromatic str.), 1430 (S=O), 1190 (C-O-C bond str.), 
1116 (C-N-C bond str.); 1H-NMR (500 MHz, CDCl3, δ/ 
ppm): 7.62 (d, J = 8.0 Hz, 2H, H-3’’ & H-5’’), 7.54 (d, J 
= 8.1 Hz, 2H, H-2’’ & H-6’’), 7.46 (distorted d, J = 1.7 
Hz, 1H, H-5’), 6.90 (d, J = 3.5 Hz, 1H, H-3’), 6.40 (dd, 
J = 1.7, 3.4 Hz, 1H, H-4’), 3.79 (br.s, 4H, CH2-2 & CH2-
6), 3.55 (s, 2H, CH2-7’’), 2.91 (m, 4H, CH2-3 & CH2-5), 
2.92-2.67 (m, 4H, CH2-2’’’ & CH2-6’’’), 1.64-1.52(m, 4H, 
CH2-3’’’ & CH2-5’’’), 1.54(m, 1H, CH2-4’’’), 0.99 (s, 3H, 
CH3-7’’’); EIMS (m/z): 431[M]+, 336 [C17H26N3O2S]+, 335 
[C17H25N3O2S]•+, 268 [C16H16N2O2]•+, 253 [C13H19NO2S]•+, 
252 [C13H18NO2S]+, 193 [C10H13N2O2]+,179 [C9H11N2O2]+, 
187 [C8H13NO2S]•+, 95 [C5H3O2]+, 98 [C6H12N]+.
2-Furyl(4-{4-[(2,6-dimethyl-1-piperidinyl)sulfonyl]
benzyl}-1-piperazinyl)(2- methanone (5g)
Light brown amorphous solid; Yield: 78%; m.p.: 91-
93 oC; HRMS: [M]•+ 445.2037 (Calcd. for C23H31N3O4S; 
445.2057); IR (KBr, cm-1) υmax: 3089 (C-H str. of aromatic 
ring), 2873 (C-H str. of aliphatic), 1658 (C=O str.), 1581 
(C=C aromatic str.), 1437 (S=O), 1181 (C-O-C bond str.), 
1117 (C-N-C bond str.); 1H-NMR (500 MHz, CDCl3, δ/ 
ppm): 7.65 (d, J = 8.2 Hz, 2H, H-3’’ & H-5’’), 7.49 (d, J = 
8.1 Hz, 2H, H-2’’ & H-6’’), 7.56 (distorted d, J = 1.5 Hz, 
1H, H-5’), 6.95 (d, J = 3.3 Hz, 1H, H-3’), 6.48 (dd, J = 1.5, 
3.3 Hz, 1H, H-4’), 3.79 (br.s, 4H, CH2-2 & CH2-6), 3.54 
(s, 2H, CH2-7’’), 2.93 (m, 4H, CH2-3 & CH2-5), 2.98 (m, 
2H, CH2-2’’’ & CH2-6’’’), 1.67-1.45 (m, 4H, CH2-3’’’ & 
CH2-5’’’), 0.96 (s, 6H, CH3-7’’’ & CH3-8’’’); EIMS (m/z): 
445 [M]+, 350 [C18H28N3O2S]+, 349 [C18H27N3O2S]•+, 268 
[C16H16N2O2]•+, 267 [C14H21NO2S]•+, 266 [C14H20NO2S]+, 
193 [C10H13N2O2]+,179 [C9H11N2O2]+, 201 [C9H15NO2S]•+, 
95 [C5H3O2]+, 112 [C7H14N]+.
2-Furyl-(4-{4-[(3,5-dimethyl-1-piperidinyl)sulfonyl]
benzyl}-1-piperazinylmethanone (5h)
Off-white amorphous solid; Yield: 89 %; m.p.: 90-92 
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oC; HRMS: [M]•+ 445.2037 (Calcd. for C23H31N3O4S; 
445.2057); IR (KBr, cm-1) υmax: 3085 (C-H str. of aromatic 
ring), 2872 (C-H str. of aliphatic), 1650 (C=O str.), 1588 
(C=C aromatic str.), 1435 (S=O), 1183 (C-O-C bond str.), 
1111 (C-N-C bond str.); 1H-NMR (500 MHz, CDCl3, δ/ 
ppm): 7.71 (d, J = 8.2 Hz, 2H, H-3’’ & H-5’’), 7.45 (d, 
J = 8.0 Hz, 2H, H-2’’ & H-6’’), 7.46 (distorted d, J = 
1.4 Hz, 1H, H-5’), 6.90 (d, J = 3.2 Hz, 1H, H-3’), 6.45 
(dd, J = 1.5, 3.4 Hz, 1H, H-4’), 3.72 (br.s, 4H, CH2-2 
& CH2-6), 3.45 (s, 2H, CH2-7’’), 2.89 (m, 4H, CH2-3 & 
CH2-5), 2.90-2.61 (m, 4H, CH2-2’’’ & CH2-6’’’), 1.59- 
1.50 (m, 2H, CH2-3’’’ & CH2-5’’’), 1.45-1.34 (m, 2H, 
CH2-4’’’), 1.01 (s, 6H, CH3-7’’’ & CH3-8’’’); EIMS (m/z): 
445 [M]+, 350 [C18H28N3O2S]+, 349 [C18H27N3O2S]•+, 268 
[C16H16N2O2]•+, 267 [C14H21NO2S]•+, 266 [C14H20NO2S]+, 
193 [C10H13N2O2]+,179 [C9H11N2O2]+, 201 [C9H15NO2S]•+, 
95 [C5H3O2]+, 112 [C7H14N]+.
Biological activity assays
Cholinesterase assays
The AChE and BChE inhibition study was performed 
according to an established method (Ellman et al., 1961). 
The percent inhibition was calculated by the following 
equation:
The IC50 (concentration at which there is 50% 
enzyme inhibition) of compounds was calculated using 
EZ-Fit Enzyme Kinetics Software (Perrella Scientific Inc. 
Amherst, USA).
Antibacterial activity
The antibacterial activity test was performed in 
sterile 96-wells microplates under aseptic environments. 
The method is rooted in the principle that microbial cell 
number increases as the microbial growth proceeds in a 
log phase of growth, which results in increased absorbance 
of broth medium (Kaspady et al., 2009; Yang et al., 2006). 
Three Gram-negative (Salmonella typhi, Escherichia coli 
and Pseudomonas aeruginosa) and two Gram-positive 
bacteria (Bacillus subtilis, Staphylococcus aureus) were 
included in the study. The organisms were maintained on 
stock culture agar medium. The test samples with suitable 
solvents and dilutions were pipette into wells (20 µg/well). 
Overnight maintained fresh bacterial culture after suitable 
dilution with fresh nutrient broth was poured into wells 
(180 µL). The initial absorbance of the culture was strictly 
maintained between 0.12-0.19 at 540 nm. The total volume 
in each well was kept to 200 µL. The incubation was done 
at 37 oC for 16-24 hours with lid on the microplate. The 
absorbance was measured, before and after incubation and 
the difference was noted as an index of bacterial growth at 
540 nm by using microplate reader. The percent inhibition 
was calculated by using the formula:
where X is absorbance in control with bacterial culture 
and Y is absorbance in test sample. Results are mean 
of triplicate (n=3, ± SEM). Ciprofloxacin was taken as 
standard.
Statistical analysis
The results are written as mean ± SEM after 
performance in three-folds and statistical analysis by 
Microsoft Excel 2010. Minimum inhibitory concentration 
(MIC) was calculated by using different dilutions (ranging 
5-30 μg/well) and EZFit Perrella Scientific Inc. Amherst 
USA software.
Hemolytic activity
Hemolytic activity was evaluated by a previously 
reported method (Sharma, Sharma, 2001; Powell, 
Catranis, Maynard, 2000). Human blood was obtained 
from volunteers according to the Department of Clinical 
Medicine and Surgery, University of Agriculture, 
Faisalabad, Pakistan. After centrifugation, separation and 
washing, the % RBCs lysis was computed by noting the 
absorbance.
Molecular docking 
To predict the bioactive conformations, various 
compounds (ligands) were docked into the binding pockets 
of the selected proteins (enzymes) by using the default 
parameters of MOE-Dock program.
Ligand preparation
The three-dimensional (3D) structures of the 
compounds synthesized were modeled by using the Build 
program of MOE 2009-10. The energies of the compounds 
were then minimized by using the default parameter of 
MOE energy minimization algorithm (gradients: 0.05, 
force field: MMFF94X). Database was created in which 
all the compounds (3D structures) were saved in the mdb 
file format for the next step of docking.
Receptor protein preparation
The 3D structures of receptor protein molecules 
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of AChE (PDB ID code: 1Zi3; Resolution: 1.69Å) 
and BChE (PDB ID code: 1POP; Resolution: 2.30Å) 
were downloaded from Protein Data Bank. All water 
molecules were removed from the receptor proteins and 
3D protonation was carried out by using Protonate 3D 
Option. Protein molecules were energy minimized by 
using the default parameters of MOE 2009-10 energy 
minimization algorithm (gradient: 0.05, Force Field: 
MMFF94X). By using default parameters of MOE-Dock 
Program, all the ligands were docked into binding sites 
of the above proteins. Re-docking procedure was also 
used to increase the validity of docking protocol (Bostro, 
Greenwood, Gottfries, 2003).
RESULTS AND DISCUSSION
The purpose of the present study was to synthesize 
new molecules and to evaluate their biological activities 
against different enzymes and various bacterial strains. 
In addition, the cytotoxicity of the new compounds was 
also evaluated. Different 2-furyl(4-{4-[(substituted)
sulfonyl]benzyl}-1-piperazinyl)methanone derivatives 
(5a-h) were synthesized in various steps as described 
in Scheme 1. The synthesis was carried out by the 
treatment of different secondary amines (1a-h) with 
4-bromomethylbenzenesulfonyl chloride (2) to obtain 
solid electrophiles, 3a-h, which were collected through 
filtration. 2-Furyl(1-piperazinyl)methanone (2-furoyl-
1-piperazine; 4) was then dissolved in acetonitrile and 
K2CO3 added, and the mixture was refluxed for 0.5 h for 
activation of this molecule. This solution was mixed with 
an equimolar amount of 1-{[4-(bromomethyl)phenyl]
sulfonyl}amines (3a-h), to form the target 2-furyl(4-{4-
[(substituted)sulfonyl]benzyl}-1-piperazinyl)methanones 
(5a-h).
Chemistry
The structural analysis of one of the compounds 
is discussed here in detail for the benefit of the reader. 
Compound 5c was synthesized as a light brown crystalline 
solid with a melting point of 60-62 oC and molecular 
formula of C21H27N3O4S, which was confirmed by EI-
MS with a [M]+ peak of 417. The distinct peak at m/z 
95 was related to the furan-2-carbaldehyde part of the 
molecule. The fragmentation pattern of this molecule is 
outlined in Figure 1. In the IR spectrum, characteristic 
peaks appeared at 3086 (C-H stretch of aromatic ring), 
2878 (C-H stretch of aliphatic), 1659 (C=O stretch), 1576 
(C=C aromatic stretch), 1426 (S=O), 1191 (C-O-C bond 
stretch) and 1109 (C-N-C bond stretch), confirming the 
presence of sulfonamide and 2-furoyl-1-piperazine ring. 
In 1H-NMR spectrum, two signals of aromatic protons 
appeared at δ 7.68 (d, J = 8.2 Hz, 2H, H-3’’ & H-5’’), 
7.47 (d, J = 8.1 Hz, 2H, H-2’’ & H-6’’), which were 
typical for 1,4-disubstituted aromatic ring. The furan 
ring showed three peaks in the aromatic region at δ 7.50-
7.47 (merged s, 1H, H-5’), 6.97 (d, J = 3.3 Hz, 1H, H-3’) 
and 6.47 (dd, J = 1.7, 3.3 Hz, 1H, H-4’). In the aliphatic 
region, signals appeared for a piperazine ring at δ 3.76 
(br.s, 4H, CH2-2 & CH2-6) and 2.98 (m, 4H, CH2-3 & 
CH2-5) for piperazine ring at δ 3.52 (s, 2H, CH2-7’’) and 
signals for a piperidine ring at δ 2.92 (m, 4H, CH2-2’’’ 
& CH2-6’’’), 1.59 (m, 4H, CH2-3’’’ & CH2-5’’’) and 1.50 
(m, 2H, CH2-4’’’) with attached sulfonamide group. The 
EIMS and 1H-NMR spectra of this molecule are shown in 
Figure 2 and Figure 3, respectively. These spectral data 
confirmed thev structure of this molecule as 2-furyl{4-[4-
(1-piperidinylsulfonyl)benzyl]-1-piperazinyl}methanone. 
Similarly, the structures of all the synthesized molecules, 
SCHEME 1 - Outline for the synthesis of 2-Furyl(4-{4-
[(substituted)sulfonyl]benzyl}-1-piperazinyl)methanone 
derivatives (5a-h). Reagents and conditions: (I) 10% Na2CO3, 
pH 9-10, Stirring at room temperature for 3-4 hours; (II) 
Acetonitrile, K2CO3, reflux for 0.5 hours (III) Reflux for 4-5 
hours after addition of electrophiles, 3a-h, separately one by 
one in each reaction.
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5a-h, were characterized by their IR, 1H-NMR and EI-MS 
spectral analysis.
Biological activities
Cholinesterase assays
The results of screening the compounds against 
cholinesterase are given as % inhibition and IC50 in 
Table I. 
Against AChE, (4-{4-[(3,5-dimethyl-1-piperidinyl)
sulfonyl]benzyl}-1-piperazinyl)(2-furyl)methanone 
(5h) was found to be an excellent inhibitor with an IC50 
of 2.91 ± 0.001 μM, compared to eserine, a reference 
standard with an IC50 of 0.04 ± 0.0001 μM, probably due 
to the presence of the 3,5-dimethyl-1-piperidinyl group. 
Among the other molecules, 2-furyl(4-{4-[(4-methyl-1-
piperidinyl)sulfonyl]benzyl}-1-piperazinyl)methanone 
(5f) and 2-furyl(4-{4-[(2-methyl-1-piperidinyl)sulfonyl]
benzyl}-1-piperazinyl)methanone (5d), with IC50 values 
of 13.72 ± 0.06 and 33.42 ± 0.05 μM, respectively, 
were found to be excellent inhibitors probably due to 
the presence of 4-methyl-1-piperidinyl and 2-methyl-1-
piperidinyl groups. 
With regard to BChE, 4-{4-[(3,5-dimethyl-1-
piperidinyl)sulfonyl]benzyl}-1-piperazinyl)(2-Furyl)
methanone (5h)  and 2furyl(4-{4-[(3-methyl-1-
piperidinyl)sulfonyl]benzyl}-1-piperazinyl)methanone 
(5e) both showed very comparable inhibitory potential 
compared to the standard used against, as evident from 
their IC50 values. The results are given in Table I. The IC50 
values of these compounds were calculated to be 4.35 ± 
0.004 and 8.33 ± 0.007 μM, respectively, compared to 
eserine with an IC50 of 0.85 ± 0.001 μM. The significant 
inhibitory potential of these molecules could have 
been attributed to the substitution of 3,5-dimethyl-1-
piperidinyl and 3-methyl-1-piperidinyl groups. In the 
future these molecules can be further investigated to 
introduce new drug candidates.
Antibacterial activity (in vitro)
All the compounds synthesized were screened 
against various Gram-positive and Gram-negative 
bacterial strains, and most of them were found to be potent 
inhibitors. The results are tabulated as % inhibition and 
MIC values in Tables II and III, respectively.
Against S. typhi, 2-furyl(4-{4-[(3-methyl-1-
FIGURE 1 - Proposed mass fragmentation pattern of 2-furyl{4-[4-(1-piperidinylsulfonyl)benzyl]-1-piperazinyl}methanone (5c).
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TABLE I - Bioactivity studies of different 2-furyl(4-{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl)methanone derivatives (5a-h)
Compound
AChE BChE Hemolytic activity
Inhibition 
% 
IC50 
(µM)
Inhibition 
% 
IC50 
(µM) % 
5a 35.67±0.16 - 41.25±0.15 - 30.12
5b 28.99±0.18 - 42.22±0.11 - 6.82
5c 76.23±0.14 51.21±0.03 52.34±0.13 372.92±0.05 10.87
5d 78.15±0.16 33.42±0.05 75.61±0.14 52.41±0.06 32.55
5e 65.45±0.11 125.28±0.08 92.44±0.12 8.33±0.007 1.66
5f 82.33±0.03 13.72±0.06 55.28±0.16 259.25±0.19 5.99
5g 63.27±0.19 165.23±0.09 57.55±0.14 217.38±0.17 35.98
5h 91.93±0.03 2.91±0.001 89.76±0.08 4.35±0.004 1.79
Eserine 91.27±1.17 0.04±0.0001 82.82±1.09 0.85±0.0001
PBS 0.09
Triton 100
NOTE: All compounds were dissolved in methanol and experiments were performed in triplicate (mean ± SEM, n=3). AChE = 
acetylcholinesterase, BChE = butyrylcholinesterase
TABLE II - Antibacterial activity (% inhibition) of different 2-furyl(4-{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl)methanone 
derivatives (5a-h)
Compound
Inhibition (%)
S. typhi (-) E. coli (-) P. aeruginosa (-) B. subtilis (+) S. aureus (+)
5a 74.48±0.97 73.65±0.68 58.37±0.80 72.93±0.23 38.38±0.62
5b 74.23±0.95 68.45±0.63 61.21±0.43 75.23±0.43 46.29±0.52
5c 69.57±0.41 59.35±0.85 52.79±0.50 62.77±0.83 44.00±0.29
5d 75.76±0.32 61.30±0.45 54.99±0.15 68.30±0.70 42.80±0.91
5e 77.73±0.14 57.40±0.60 42.99±0.19 54.67±0.65 47.90±0.42
5f 78.58±0.32 58.95±0.74 54.39±0.27 63.27±0.20 45.76±0.57
5g 67.14±0.29 63.13±0.53 73.84±0.17 66.43±0.82 45.23±0.73
5h 65.30±0.83 70.87±0.46 66.36±0.82 74.61±0.18 44.13±0.49
Ciprofloxacin 91.05±0.68 92.32±0.42 92.50±0.34 92.02±053 91.44±0.64
TABLE III - Antibacterial activity (MIC) and hemolytic activity of the different 2-furyl(4-{4-[(substituted)sulfonyl]benzyl}-1-
piperazinyl)methanone derivatives (5a-h)
Compound
MIC (µM)
S. typhi (-) E. coli(-) P. aeruginosa (-) B. subtilis (+) S. aureus (+)
5a 9.13±0.28 9.86±0.35 15.28±0.66 9.56±0.82 _
5b 9.19±0.74 10.58±0.42 14.53±0.74 9.25±0.18 _
5c 10.31±0.25 15.95±0.63 18.33±0.61 14.87±0.56 _
5d 9.10±0.69 14.89±0.79 17.85±0.85 10.14±0.62 _
5e 8.58±0.26 16.96±0.11 _ 17.92±0.45 _
5f 8.62±0.44 16.75±0.52 18.76±0.12 11.41±0.56 _
5g 13.84±0.19 12.35±0.39 9.10±0.43 16.91±0.29 _
5h 10.51±0.76 12.24±0.84 13.61±0.96 11.58±0.93 _
Ciprofloxacin 7.45±0.58 7.16±0.58 7.14±0.18 7.29±0.90 7.80±0.19
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piperidinyl)sulfonyl]benzyl}-1-piperazinyl)methanone 
(5e) and 2-furyl(4-{4-[(4-methyl-1-piperidinyl)sulfonyl]
benzyl}-1-piperazinyl)methanone (5f) had the lowest 
MIC values, 8.58 ± 0.26 and 8.62 ± 0.44 μM, respectively, 
most probably due to the presence of 3-methyl-1-
piperidinyl and 4-methyl-1-piperidinyl. In the case of 
E. coli, 2-furyl{4-[4-(4-morpholinylsulfonyl)benzyl]-
1-piperazinyl}methanone (5a) showed the lowest MIC 
value of 9.86 ± 0.35 μM, likely because of the presence 
of the 4-morpholinyl group. In the case of P. aeroginosa, 
(4-{4-[(2,6-dimethyl-1-piperidinyl)sulfonyl]benzyl}-1-
piperazinyl)(2-furyl)methanone (5g) exhibited the lowest 
MIC value of 9.10 ± 0.43 μM, which might have been 
due to presence of the 2,6-dimethyl-1-piperidinyl group. 
Against B. subtilis, (4-{4-[(3,5-dimethyl-4-morpholinyl)
sulfonyl]benzyl}-1-piperazinyl)(2-furyl)methanone 
(5b) showed the lowest MIC value of 9.25 ± 0.18 μM, 
presumably owing to the presence of the 3,5-dimethyl-
4-morpholinyl group. Surprisingly, all molecules tested 
were inactive against S. aureus.
Hemolytic activity
The highest hemolytic activity was shown by 5g 
(35.98%), higher than the positive control (Triton X-100). 
The lowest activity was shown by 5e (1.66%) but higher 
than the negative control (PBS), as shown in Table I. 
Some of these molecules might be further tested for 
their application in drug designing programs because of 
moderate toxicity.
Computational Docking
It is clear from Figure 2 (2D and 3D) that compound 
5h was deeply bound in the binding pockets of AChE 
by making two important interactions with the amino 
acid residues Asp211 and Trp300. Asp211 interacted 
strongly with the nitrogen of the piperazine ring of the 
ligand through Mn++, giving a bond length of 2.19 Å. A 
second arene-arene interaction was made between Trp300 
and furyl rings with a bond distance of 3.60 Å. Val210, 
Asp302, Glu303 and Phe121 were also present in the 
nearby vicinity.
Similarly, molecule 5f showed two interactions with 
this enzyme. Lys125 interacted strongly with the sulfonyl 
oxygen of the ligand through side chain donor interaction. 
The bond length calculated was 2.57 Å. Tyr126 made 
an arene-arene interaction with the benzyl ring of the 
compound, giving a bond distance of 3.77 Å, as shown in 
Figure 3 (2D and 3D).
The in silico study with butyrylcholinesterase 
(BChE) revealed that 5h also and another compound, 5e, 
exhibited considerable interaction. It was inferred that 
FIGURE 2 -  The 2D and 3D interact ion analysis  of 
4-{4-[(3,5-dimethyl-1-piperidinyl)sulfonyl]benzyl}-1-
piperazinyl)(2-furyl)methanone (5h) with acetylcholinesterase.
FIGURE 3 - The 2D and 3D interaction analysis of 2-furyl(4-
{4-[(4-methyl-1-piperidinyl)sulfonyl]benzyl}-1-piperazinyl)
methanone (5f) with acetylcholinesterase.
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5h exhibited two interactions. The first side chain donor 
interaction was between Thr120 and the sulfonyl oxygen 
with a distance of 3.53 Å, while the second arene-cation 
interaction was between His438 and the furoyl ring of the 
ligand with a bond length of 3.8 9Å (Figure 4; 2D and 3D).
In the same way, compound 5e had two interactions 
with the active site residues Thr120 and Trp82. Thr120 
had a strong side chain donor interaction with the sulfonyl 
oxygen, showing a bond distance of 3.56 Å, but Trp82 
produced an arene-arene interaction with the furoyl ring, 
showing a bond length of 4.06Å (Figure 5; 2D and 3D). 
Met437, Gly116 and His438 were also present very close 
to the ligand.
CONCLUSION
The synthesized compounds were confirmed by 
spectral data. It was evident from enzyme inhibition 
analysis that compound 5h exhibited potent inhibitory 
activity against AChE and BChE, with IC50 of 2.91 ± 
0.001 and 4.35±0.004 μM, respectively, as compared to 
the standard eserine, with IC50 of 0.04 ± 0.0001 and 0.85 
± 0.001 μM, which could be attributed to the presence of 
the 3,5-dimethyl-1-piperidinyl group in this molecule. 
These results were fully supported by their in silico study. 
Putting S. aureus aside, all of the synthesized molecules 
were active against the Gram-positive and Gram-negative 
bacterial strains tested, except compound 5e, which was 
inactive against P. aeroginosa. The hemolytic study was 
also carried out to evaluate the cytotoxicity profile of the 
synthesized molecules. It was inferred from the results 
that most of molecules were moderately toxic. Hence, 
these molecules could be recommended as suitable 
therapeutic entrants in a drug development program for 
the pharmaceutical industry.
F I G U R E  4  -  The  2D  and  3D  in t e r ac t i on  ana ly s i s 
o f  4 - { 4 - [ ( 3 , 5 - d i m e t h y l - 1 - p i p e r i d i n y l ) s u l f o n y l ]
benzyl}-1-piperazinyl)(2-furyl)methanone (5h) against 
butrylcholinesterase. FIGURE 5 - The 2D and 3D interaction analysis of 2-furyl(4-
{4-[(3-methyl-1-piperidinyl)sulfonyl]benzyl}-1-piperazinyl)
methanone (5e) with butrylcholinesterase.
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FIGURE 6 - EIMS spectrum of 2-furyl{4-[4-(1-piperidinylsulfonyl)benzyl]-1-piperazinyl}methanone (5c).
FIGURE 7 - 1H-NMR spectrum of -furyl{4-[4-(4-morpholinylsulfonyl)benzyl]-1-piperazinyl}methanone (5a).
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